Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fennec Pharmaceuticals Inc. (FENC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed under its Exchange Act reporting obligations. Fennec is a specialty pharmaceutical company focused on PEDMARK®, a sodium thiosulfate injection indicated to reduce the risk of cisplatin-induced ototoxicity in certain pediatric cancer patients.
Recent Form 8-K filings describe material definitive agreements and financing activities, such as an underwriting agreement for an underwritten registered public offering of common shares and subscription agreements for a non-brokered offering of common shares in Canada. These filings outline key terms of the offerings, the number of shares issued, the public offering price and the use of proceeds.
Other 8-K reports detail a Waiver and Redemption Agreement with Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, under which Fennec agreed to repurchase and redeem its remaining senior secured floating rate convertible notes. The company reports that, after completing this transaction, all payment obligations under the notes were satisfied in full, and related news releases are incorporated by reference in the filings.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools can help readers quickly identify the purpose of each filing, such as equity offerings, debt redemptions or other corporate events, and understand how they relate to Fennec’s ongoing commercialization of PEDMARK® and its capital structure. Users can also track exhibits referenced in the 8-Ks, including underwriting agreements, subscription agreements, legal opinions and press releases.
Fennec Pharmaceuticals Inc. reported an insider transaction by its Chief Financial Officer, Robert Andrade. On 01/15/2026, he exercised 10,000 stock options with an exercise price of $2.45 per share, acquiring 10,000 common shares.
Following the transaction, Andrade directly beneficially owned 201,100 common shares and held 826,567 stock options that remained outstanding. The shares were acquired through the exercise of an option contract with a strike price of $2.45 and an expiration date of July 5, 2026.
Fennec Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with Southpoint report beneficial ownership of 2,744,741 Common Shares, representing 8.0% of the company. These shares are held by Southpoint Master Fund, LP, with related management and general partner entities, and by John S. Clark II in his capacities with those entities.
The reported ownership percentage is based on 34,153,496 outstanding Common Shares, as disclosed in a Prospectus Supplement filed on November 18, 2025. The reporting parties state that each of them disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported exercising stock options and acquiring common shares of the company. On January 7, 2026, he exercised 14,184 stock options at an exercise price of $2.45 per share, which resulted in acquiring 14,184 common shares. After this transaction, he beneficially owned 191,100 common shares directly and held 836,567 stock options directly.
Fennec Pharmaceuticals director reports vested share award
A director of Fennec Pharmaceuticals Inc. reported the acquisition of 5,208 common shares of the company on 12/01/2025. The filing shows these shares were released from restrictions tied to awards originally granted on 3/31/2023 and 5/16/2024, so no purchase price was paid and the transaction is recorded at $0 per share.
Following this vesting event, the director now beneficially owns 87,526 common shares, held directly. The transaction was reported on a Form 4 filed for a single reporting person in the capacity of director of Fennec Pharmaceuticals Inc. (FENC).
Fennec Pharmaceuticals (FENC) reported an insider share sale by a major holder. On 11/18/2025, an affiliated fund of Southpoint, for which John S. Clark II and related Southpoint entities serve as general partners and managers, sold 19,341 shares of Fennec common stock in open-market transactions. The weighted average sale price was $8.7921 per share across trades executed between $8.75 and $8.845 per share. After this sale, the reporting persons collectively report 3,744,741 shares of Fennec common stock beneficially owned indirectly, while each disclaims beneficial ownership beyond their pecuniary interest.
Fennec Pharmaceuticals Inc. (FENC) has fully repurchased and redeemed its remaining senior secured floating rate convertible notes held by Petrichor. On November 17, 2025, the company paid a total redemption price of $21,729,455.30, consisting of $19,476,655.48 in outstanding principal (including accrued PIK interest), $305,134.27 in accrued interest, and a $1,947,665.55 redemption fee. This follows an earlier repurchase and redemption of notes with an aggregate principal amount of $13,000,000. After this transaction, all payment obligations under the notes have been satisfied in full.
Fennec Pharmaceuticals Inc. (FENC) has filed a Form S-8 to register securities for issuance under its Fennec Pharmaceuticals Inc. 2020 Equity Incentive Plan. This filing allows the company to issue equity-based awards such as stock options or other equity incentives to employees, directors and other eligible participants under that plan. The registration statement incorporates by reference Fennec’s latest Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, specified Current Reports on Form 8-K and its Form 8-A description of capital stock. The company also outlines how directors and officers may be indemnified under British Columbia corporate law and its Articles, and confirms it maintains liability insurance for directors and officers. Standard undertakings are included for future amendments and for how later Exchange Act reports will be treated as part of this registration.
Fennec Pharmaceuticals Inc. (FENC) entered into subscription agreements with certain existing institutional shareholders to sell an aggregate of 670,000 common shares at US$7.50 per share. This equity offering, made under a listed issuer financing exemption in Canada and registered on the company’s Form S-3 shelf, closed on November 18, 2025 and generated aggregate gross proceeds of US$5,025,000 before expenses.
Fennec plans to use the first portion of these proceeds to help repurchase and redeem its outstanding Petrichor convertible notes for an aggregate price of approximately US$21,729,455 on or before November 19, 2025, with any remaining net proceeds allocated to working capital and general corporate purposes.
Fennec Pharmaceuticals Inc. is registering and issuing 670,000 common shares at $7.50 per share, for aggregate gross proceeds of $5,025,000. These shares are being sold directly to certain existing institutional shareholders in Canada (excluding Quebec) under a listed issuer financing exemption, without using a broker or placement agent. The company recently completed a separate underwritten public offering of 5,366,667 common shares at $7.50 per share, raising approximately $40,250,000 in gross proceeds.
Combined net proceeds of approximately $42,014,502 are intended first to repurchase and redeem the Petrichor convertible notes for about $21,729,455, including outstanding principal, accrued interest and a redemption fee, with the balance earmarked for working capital and general corporate purposes. After giving effect to both offerings, Fennec’s as adjusted net tangible book value as of September 30, 2025 would rise from approximately $(0.16) to $1.10 per share, resulting in immediate dilution of about $6.40 per share to new investors.
Fennec Pharmaceuticals Inc. (FENC) received a Form 4 reporting sales of its common stock by a director and more than 10% owner group affiliated with Southpoint. On 11/14/2025, the reporting persons sold 160,100 shares of common stock at a weighted average price of $7.9977 per share. On 11/17/2025, they sold an additional 85,918 shares at a weighted average price of $8.7897 per share. Following these transactions, the group reports indirect beneficial ownership of 3,764,082 Fennec common shares through Southpoint Master Fund, LP and its related investment entities. The filing notes that each reporting person disclaims beneficial ownership beyond its or his pecuniary interest.